Recruiting
Phase 1

MK-1406

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT07743151

Conditions

Healthy

Eligibility Criteria

Sex: All

Age: 18 - 64

Healthy Volunteers: Accepted

Interventions

MK-1406

Study Details

Brief summary:

The purpose of this trial is to compare what happens to MK-1406 in the body of healthy participants when it is given as 2-injections and 3-injections. Researchers also want to learn about the safety of MK-1406 and if people tolerate it.

Conditions

Healthy

Study ID

NCT07743151

Start date

Sep 10, 2026

Status verified date

Oct, 2026

Completion date

Feb 5, 2027

Anticipated

Primary completion date

Feb 5, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 64

Healthy Volunteers: Accepted

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Is in good health
  • Has body mass index (BMI) 18.0 to 32.0 kg/m\^2

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • History of clinically significant endocrine, Gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • History of cancer (malignancy)

Study Design

Enrollment

400 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: MK-1406 3-Injections

Participants receive 3 subcutaneous (SQ) injections of MK-1406 on Day 1.

experimental: MK-1406 2-Injections

Participants receive 2 SQ injections of MK-1406 on Day 1.

Interventions

MK-1406

Subcutaneous administration

Primary outcome measure

  • Part 1: Area Under the Concentration Time Curve From Time 0 to 4 Weeks (AUC0-4w) of MK-1406 [ Time Frame: Predose and at designated timepoints up to 4 weeks postdose ]
  • Part 1 and Part 2: Number of Participants Who Experience One or More Adverse Events (AEs) [ Time Frame: Up to approximately 43 days postdose ]
  • Part 1 and Part 2: Number of Participants Who Experience At Least One Solicited Injection-Site Reaction [ Time Frame: Up to approximately 7 days postdose ]
  • Part 1 and Part 2: Number of Participants Who Discontinue Study Due to an AE [ Time Frame: Up to approximately 43 days postdose ]

Central Contacts and Locations

Central contacts

Toll Free Number

1-888-577-8839Trialsites@msd.com

Locations

Research Centers of America ( Hollywood ) ( Site 0008)

Recruiting

Hollywood, Florida, United States, 33024

Contacts

Study Coordinator

954-990-7649

QPS-MRA, LLC ( Site 0007)

Recruiting

South Miami, Florida, United States, 33143

Contacts

Study Coordinator

305-722-0970

Parexel Baltimore EPCU ( Site 0010)

Recruiting

Baltimore, Maryland, United States, 21225

Contacts

Study Coordinator

667-210-5300

Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0002)

Recruiting

Springfield, Missouri, United States, 65802

Contacts

Study Coordinator

417-831-2048

Hassman Research Institute Marlton Site ( Site 0001)

Recruiting

Marlton, New Jersey, United States, 08053

Contacts

Study Coordinator

856-452-9901

Velocity Clinical Research, Cleveland ( Site 0005)

Recruiting

Cleveland, Ohio, United States, 44122

Contacts

Study Coordinator

216-682-0320

ICON Early Phase Services ( Site 0004)

Recruiting

San Antonio, Texas, United States, 78232

Contacts

Study Coordinator

210-225-5437

More Information

Sponsor

Merck Sharp & Dohme LLC

Last update posted

Oct 27, 2026

Last verified

Oct, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-12. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2026-10-27. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.